2022
Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites.
Sun TY, Zhao L, Van Hummelen P, Martin B, Hornbacker K, Lee H, Xia LC, Padda SK, Ji HP, Kunz P. Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites. Endocrine Related Cancer 2022, 29: 665-679. PMID: 36165930, PMCID: PMC10043760, DOI: 10.1530/erc-22-0015.Peer-Reviewed Original ResearchConceptsHigh-grade neuroendocrine neoplasmsDiverse primary sitesG3 NENNeuroendocrine neoplasmsPrimary siteHigh tumor mutation burdenExploratory genomic analysisTumor mutation burdenPoor survival outcomesMutations/MbDifferent primary sitesOrgan of originRare cancer typesSurvival outcomesWorse prognosisRare tumorCell cycling pathwaysMutation burdenTherapeutic implicationsClinical standpointSomatic copy number alterationsCopy number alterationsCancer typesNeoplasmsUpregulation of oncogenes
2021
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: clinical characteristics and progression to carcinoid tumour
Sun TY, Hwang G, Pancirer D, Hornbacker K, Codima A, Lui NS, Raj R, Kunz P, Padda SK. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: clinical characteristics and progression to carcinoid tumour. European Respiratory Journal 2021, 59: 2101058. PMID: 34795035, PMCID: PMC8792466, DOI: 10.1183/13993003.01058-2021.Peer-Reviewed Original ResearchConceptsDiffuse idiopathic pulmonary neuroendocrine cell hyperplasiaIdiopathic pulmonary neuroendocrine cell hyperplasiaPulmonary neuroendocrine cell hyperplasiaElderly white womenNeuroendocrine cell hyperplasiaBasement membraneSuch hyperplasiaClinical characteristicsCarcinoid tumorsCell hyperplasiaIdentifiable causeLung diseasePreinvasive lesionsRare diseaseTumorsWhite womenNeuroendocrine cellsLung nodulesHyperplasiaTumourletsDiseaseNodulesNeoplasmsLesionsYears
2020
Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities
Shaheen S, Moradi F, Gamino G, Kunz PL. Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities. Current Treatment Options In Oncology 2020, 21: 25. PMID: 32172368, DOI: 10.1007/s11864-020-0711-9.Peer-Reviewed Original ResearchConceptsPeptide receptor radionuclide therapySomatostatin analoguesToxicity of PRRTOpinion statementNeuroendocrine tumorsMetastatic neuroendocrine tumorsLandscape of treatmentReceptor radionuclide therapyRecent treatment advancesTreatment of NETsPatient selectionNeuroendocrine tumorsTreatment advancesSomatostatin receptorsMinimal response rateRadionuclide therapyResponse rateHeterogenous groupTherapyTumor cellsBiological hallmarksTumorsTreatmentNETsIndolentNeoplasms
2016
Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors
Narayanan S, Kunz PL. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. Hematology/Oncology Clinics Of North America 2016, 30: 163-177. PMID: 26614375, DOI: 10.1016/j.hoc.2015.09.008.Peer-Reviewed Original ResearchConceptsSomatostatin analoguesNeuroendocrine tumorsRole of SSAsTreatment of NETsPeptide receptor radionuclide therapyMetastatic neuroendocrine tumorsHormone-related symptomsReceptor radionuclide therapyRare epithelial neoplasmLocal therapySymptom managementTumor controlNeuroendocrine differentiationEffective therapyEpithelial neoplasmsDisease CenterPromising treatmentRadionuclide therapyTumor growthTherapyTreatmentTumorsSurgeryNeoplasmsLung
2015
Carcinoid and Neuroendocrine Tumors: Building on Success
Kunz PL. Carcinoid and Neuroendocrine Tumors: Building on Success. Journal Of Clinical Oncology 2015, 33: 1855-1863. PMID: 25918282, DOI: 10.1200/jco.2014.60.2532.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoid TumorCell DifferentiationChemoembolization, TherapeuticChemotherapy, AdjuvantHumansNeoplasm StagingNeuroendocrine TumorsPatient SelectionPrecision MedicinePredictive Value of TestsRadiopharmaceuticalsTreatment OutcomeBeyond Biologics: Is there a Role for Systemic Cytotoxic Chemotherapy in Neuroendocrine Tumors?
Narayanan S, Kunz P. Beyond Biologics: Is there a Role for Systemic Cytotoxic Chemotherapy in Neuroendocrine Tumors? International Journal Of Endocrine Oncology 2015, 2: 13-20. DOI: 10.2217/ije.14.37.Peer-Reviewed Original ResearchManagement of NETsNeuroendocrine tumorsCytotoxic chemotherapySystemic cytotoxic chemotherapyCurrent treatment guidelinesPresent clinical trialGroup of biologicallyBiologic therapyTreatment guidelinesClinical trialsHeterogeneous neoplasmsChemotherapyDegree of responsivenessTherapyTumorsNeoplasmsTrialsBiologicsRole of somatostatin analogues in the treatment of neuroendocrine tumors.
Narayanan S, Kunz PL. Role of somatostatin analogues in the treatment of neuroendocrine tumors. Journal Of The National Comprehensive Cancer Network 2015, 13: 109-17; quiz 117. PMID: 25583773, DOI: 10.6004/jnccn.2015.0012.Peer-Reviewed Original ResearchConceptsNeuroendocrine tumorsSomatostatin analoguesTumor controlTreatment of NETsSystemic tumor controlHormone-related symptomsManagement of patientsRare epithelial neoplasmAdvanced diseaseHormone excessSymptom managementNeuroendocrine differentiationEpithelial neoplasmsGastrointestinal tractPatientsTumorsTreatmentDiarrheaNeoplasmsLungSerotoninSyndromeSymptomsManagementMainstay